TrialAnnals of the rheumatic diseases2015

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.

Rene Westhovens et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.